Damora Therapeutics, Inc. filings document public-company governance, executive compensation, auditor matters, leadership changes, and capital-structure disclosures for its biotechnology business. Recent 8-K reports cover changes in certifying accountant and principal financial officer responsibilities, while proxy materials describe compensation and governance matters.
The company’s regulatory record also reflects its Delaware corporate status, Nasdaq-listed common stock, equity-award arrangements, and disclosure controls around material events following its transition to a mutCALR-focused biotechnology pipeline.
Damora Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders as a virtual-only event on June 17, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on April 22, 2026, when 60,303,212 common shares were outstanding, may vote.
Stockholders will elect two Class III directors to terms ending at the 2029 meeting, cast an advisory “say‑on‑pay” vote on named executive officer compensation, choose the frequency of future say‑on‑pay votes, and ratify Ernst & Young LLP as independent auditor for 2026.
The proxy statement outlines board and committee structure, director independence, executive and director pay, severance and change‑in‑control protections, and ownership and governance practices. It also notes the November 2025 Damora asset acquisition and the March 2026 rebranding from Galecto to Damora Therapeutics.
Damora Therapeutics, Inc. ownership filing: Paramora Holding LLC reports beneficial ownership of 2,045,473 shares of Common Stock, representing 3.39% of the class. The filing cites 60,303,212 shares outstanding as of March 17, 2026 and is signed on April 23, 2026.
The filing is an amendment to a Schedule 13G, noting ownership and voting/dispositive powers (sole voting power 2,045,473, sole dispositive power 2,045,473), and states the position is 5% or less of the class.
Paragon Therapeutics, Inc. amended its Schedule 13G to report beneficial ownership of 2,045,473 shares of Damora Therapeutics common stock. The filing states this position represents 3.39% of the class, calculated using 60,303,212 shares outstanding as of March 17, 2026 reported in Damora's Annual Report on Form 10-K. Paragon lists sole voting and sole dispositive power over the shares and is organized in Delaware. The amendment is signed by Keri Lantz, Chief Financial Officer on April 23, 2026.
Damora Therapeutics, Inc. changed its independent auditor. On April 17, 2026, the Audit Committee dismissed EY Godkendt Revisionspartnerselskab as the independent registered public accounting firm and appointed Ernst & Young LLP (EY US) effective immediately.
EY Denmark’s reports on the Company’s financial statements for 2025 and 2024 contained no adverse or qualified opinions, although the 2024 report included an explanatory paragraph about the Company’s ability to continue as a going concern. The Company reports no disagreements or reportable events with EY Denmark and states that it did not consult EY US on accounting or auditing matters before the engagement.
Damora Therapeutics director and officer Jennifer Jarrett received new equity awards as compensation. On March 30, 2026, she was granted stock options to purchase 1,500,000 shares of common stock at an exercise price of $25.50 per share, expiring March 30, 2036. The options vest 25% on March 30, 2027 and then in equal monthly installments through March 30, 2030, subject to continued service. She also received 500,000 restricted stock units, each representing one share of common stock, vesting 25% on each anniversary of the grant date over four years, also conditioned on continued service. Following these awards, she directly holds 500,000 shares of common stock and 1,500,000 options.
Damora Therapeutics, Inc. filed an initial insider ownership report for Jennifer Jarrett, who is listed as both a director and an officer (title noted as “See Remarks”). This Form 3 does not report any stock purchases, sales, option exercises, or other transactions in Damora Therapeutics shares.
Damora Therapeutics, Inc. reported that its General Counsel, Winslow Garrett, received a grant of stock options covering 250,000 shares of common stock. The options have an exercise price of $23.05 per share and expire on March 23, 2036.
According to the terms, the award will vest 25% on March 23, 2027 and then in equal monthly installments through March 23, 2030, conditioned on continued service. Following this grant, Garrett holds 250,000 stock options directly.
Damora Therapeutics, Inc. director Turtle Cameron received a grant of stock options covering 37,313 shares of common stock. The options carry an exercise price of $23.05 per share and expire on March 23, 2036.
The award vests in equal monthly installments through March 23, 2029, as long as Cameron continues to provide service to the company. Following this grant, Cameron holds stock options for 37,313 underlying shares directly, reflecting a compensation-related equity award rather than an open-market share purchase or sale.
Damora Therapeutics director Michael Landsittel received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share and expires on March 23, 2036. It vests in equal monthly installments through March 23, 2029, contingent on his continued service. Following this grant, he holds options for 37,313 shares directly.
Damora Therapeutics, Inc. reported a Form 4 showing a grant of stock options linked to Fairmount-managed investment vehicles. An option for 37,313 shares of common stock with a $23.05 exercise price was awarded and is held indirectly by Peter Harwin for one or more Fairmount funds.
The option vests in equal monthly installments through March 23, 2029, contingent on Harwin’s continued service to Damora. Under his arrangement with Fairmount, any net cash or stock from this option must be turned over to Fairmount for the benefit of the relevant Fairmount fund, and the parties disclaim beneficial ownership beyond their pecuniary interest.